Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial Although all authors completed ...
In 2001, imatinib was the first proof that small molecule inhibitors targeting molecular drivers of cancer could be an ...
The enduring impact that imatinib (Gleevec, Novartis Pharmaceuticals) has made on the treatment of chronic myelogenous leukemia (CML), as well as on the whole field of oncology, has been highlighted ...
June 6, 2011 (Chicago, Illinois) — Extended adjuvant treatment with imatinib (Gleevec) improves survival in patients with high-risk gastrointestinal stromal tumors (GIST). Imatinib administered for 3 ...
The Appraisal Committee considered evidence submitted by Novartis Pharmaceuticals and a review of this submission by the Evidence Review Group (ERG). ACOSOG Z9001 was a randomised, double‑blind, ...
We report the case of a 16-year-old male who was initially diagnosed with Ph-positive ALL at the age of 14 years. He presented with poor prognostic factors, including a WBC count of 390 × 10 9 per L ...
Interim results of the randomized, phase 3 PhALLCON trial indicate ponatinib’s benefit over imatinib in frontline treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), ...
We report the case of a nulliparous, 70-year-old woman with long-standing type 2 diabetes mellitus who had regression of the disease during treatment of chronic myeloid leukemia with imatinib, an ...
Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference. The study investigated ...
Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference. The study investigated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results